Instylla Logo

Press Release

Instylla Announces Completion of $30MM EQUITY Financing

Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., – August 15, 2023 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with continued participation from the…

Read More

Instylla Announces Enrollment of Initial Patient in the Prospective Multicenter “HALT” Study

Pivotal study to evaluate Embrace™ Hydrogel Embolic System for the embolization of arterial bleeds in the peripheral vasculature BEDFORD, Mass., – January 10, 2023 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patient in the HALT Study¹ for the treatment of…

Read More

Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models

BEDFORD, Mass., – July 26, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluated[i] the ability…

Read More

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

BEDFORD, Mass., March 15, 2022/PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm…

Read More

Instylla Announces Enrollment of Initial Patients in the Embrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial

BEDFORD, Mass., March 30, 2021 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patients in the Embrace Hydrogel Embolic System (HES™) global randomized clinical trial for the treatment of hypervascular tumors. As demonstrated previously in the completed First-in-Human (FIH) study,…

Read More

Instylla Announces Completion of Series B Financing

Financing to see Instylla through US Pivotal and other clinical trials BEDFORD, Mass., Oct. 14, 2020 /PRNewswire/ — Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing.  Participants in this latest round of financing included the new investors Excelestar Ventures, Catalyst…

Read More